CERTARA INC (CERT) Stock News
NASDAQ:CERT - Nasdaq - US15687V1098 - Common Stock - Currency: USD
CERT Latest News, Press Relases and Analysis
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
CERTARA APPOINTS DR. ADRIAN MCKEMEY AS PRESIDENT OF DRUG DEVELOPMENT SOLUTIONS...
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions
McKemey joins Certara to accelerate growth of its strategic drug development solutions
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance
Certara Reports Fourth Quarter 2024 Financial Results
Issues Full Year 2025 Financial Guidance...
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance...
Certara to Report Fourth Quarter and Full Year 2024 Financial Results on February 26th, 2025 and Participate in Upcoming Investor Conferences
RADNOR, Pa., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it...
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Full-Year 2024 Revenue of $384.4 million, Bookings of $445.3 millionConfirms Adjusted EBITDA within Guidance Range of $120 million to $124 million ...
Certara Reports Preliminary Fourth Quarter and Full Year 2024 Financial Results
Certara Completes Acquisition of Chemaxon
Certara completes acquiring Chemaxon, a leading cheminformatics company that develops scientific informatics software used by the life sciences industry....
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that...
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list...
Certara Showcases 2024 Research Wins With Over 100 Papers Published
The company celebrates the 12 scientists included in the Stanford/Elsevier top 2% cited researchers list
Certara Reports Third Quarter 2024 Financial Results
Updates Full Year 2024 Financial Guidance
Certara to Participate in the Stephens Annual Investment Conference
RADNOR, Pa., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that...
Certara to Participate in the Stephens Annual Investment Conference
Certara Appoints John Reynders as New Independent Board Member
Certara today announced the appointment of John Reynders, PhD to its Board of Directors, effective October 15, 2024. ...
Certara Appoints John Reynders as New Independent Board Member
MaxCyte Appoints Cynthia Collins to its Board of Directors
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
RADNOR, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it...
Certara to Report Third Quarter 2024 Financial Results on November 6th, 2024
Certara Completes Acquisition of Chemaxon
The combined organization offers life sciences companies predictive biosimulation and scientific informatics capabilities, improving certainty in decision-making from discovery through commercialization.
Certara’s Simcyp Consortium Celebrates 25th Anniversary
The pre-competitive scientific research consortium of top pharmaceutical companies remains a critical force in advancing qualified PBPK modeling and simulation to further drug development and regulatory decisions
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Certara shared the results from its collaboration with Ichnos Glenmark Innovation (IGI) on the first-in-human dose prediction and selection for ISB 2001. ...
Certara & Ichnos Glenmark Innovation Collaboration Optimizes Dosing Strategy for Potential First-In-Class Cancer Drug
Preclinical research on the trispecific antibody, ISB 2001, published in Nature Cancer leveraged virtual trials to select a higher starting dose that would lower costs and reduce cycle times
Certara to Participate in Upcoming Investor Conferences
RADNOR, Pa., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that...
Certara to Participate in Upcoming Investor Conferences
Certara Launches Phoenix™ Version 8.5 Drug Development Software
Certara today announced the launch of Phoenix™ version 8.5 software, the pharmaceutical industry's gold standard in PK/PD modeling and simulation....